196 related articles for article (PubMed ID: 10221083)
21. A review of Chlamydia pneumoniae and atherosclerosis.
Lindholt JS; Fasting H; Henneberg EW; Ostergaard L
Eur J Vasc Endovasc Surg; 1999 Apr; 17(4):283-9. PubMed ID: 10204048
[TBL] [Abstract][Full Text] [Related]
22. Inflammation in atherosclerosis and implications for therapy.
Paoletti R; Gotto AM; Hajjar DP
Circulation; 2004 Jun; 109(23 Suppl 1):III20-6. PubMed ID: 15198962
[TBL] [Abstract][Full Text] [Related]
23. Antibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis.
Fong IW
J Infect Dis; 2000 Jun; 181 Suppl 3():S514-8. PubMed ID: 10839750
[TBL] [Abstract][Full Text] [Related]
24. Chlamydia pneumoniae and cytomegalovirus seropositivity, inflammatory markers, and the risk of myocardial infarction at a young age.
Gattone M; Iacoviello L; Colombo M; Castelnuovo AD; Soffiantino F; Gramoni A; Picco D; Benedetta M; Giannuzzi P
Am Heart J; 2001 Oct; 142(4):633-40. PubMed ID: 11579353
[TBL] [Abstract][Full Text] [Related]
25. Transmission of Chlamydia pneumoniae infection from blood monocytes to vascular cells in a novel transendothelial migration model.
Rupp J; Koch M; van Zandbergen G; Solbach W; Brandt E; Maass M
FEMS Microbiol Lett; 2005 Jan; 242(2):203-8. PubMed ID: 15621438
[TBL] [Abstract][Full Text] [Related]
26. [Chlamydia pneumoniae and atherosclerosis].
Marre R; Essig A
Dtsch Med Wochenschr; 1997 Sep; 122(36):1092-5. PubMed ID: 9333534
[No Abstract] [Full Text] [Related]
27. Secondary prevention of atherosclerosis through chlamydia pneumoniae eradication (SPACE Trial): a randomised clinical trial in patients with peripheral arterial disease.
Vainas T; Stassen FR; Schurink GW; Tordoir JH; Welten RJ; van den Akker LH; Kurvers HA; Bruggeman CA; Kitslaar PJ
Eur J Vasc Endovasc Surg; 2005 Apr; 29(4):403-11. PubMed ID: 15749042
[TBL] [Abstract][Full Text] [Related]
28. [Atherosclerosis and inflammation--role of chlamydia pneumoniae infection what do we know to date?].
Fudal M; Wilczewski P
Wiad Lek; 2004; 57(3-4):151-5. PubMed ID: 15307523
[TBL] [Abstract][Full Text] [Related]
29. Chlamydia pneumoniae and cardiovascular disease: an evolutionary perspective on infectious causation and antibiotic treatment.
Ewald PW; Cochran GM
J Infect Dis; 2000 Jun; 181 Suppl 3():S394-401. PubMed ID: 10839723
[TBL] [Abstract][Full Text] [Related]
30. [The role of Chlamydia pneumoniae in atherogenesis].
Barsukov AE; Svetlikov AV
Vestn Khir Im I I Grek; 2000; 159(3):104-8. PubMed ID: 10983358
[No Abstract] [Full Text] [Related]
31. Emerging relations between infectious diseases and coronary artery disease and atherosclerosis.
Fong IW
CMAJ; 2000 Jul; 163(1):49-56. PubMed ID: 10920732
[TBL] [Abstract][Full Text] [Related]
32. Does Chlamydia pneumoniae cause coronary atherosclerosis and should we all take macrolides?
Shafran SD; Conley JM
Can J Cardiol; 1997 Nov; 13(11):1017-9. PubMed ID: 9413231
[No Abstract] [Full Text] [Related]
33. [Morphological aspects of atherosclerosis lesion: past and present].
Gaudio E; Carpino G; Grassi M; Musca A
Clin Ter; 2006; 157(2):135-42. PubMed ID: 16817503
[TBL] [Abstract][Full Text] [Related]
34. [Effect of chronic Chlamydia infection with non-specific inflammation on cardiovascular complications in acute myocardial infarct].
Jaber AJ; Murín J; Hricák V; Tomasovic B; Kinová S; Kozlíková K; Ghanem W; Radman A
Vnitr Lek; 2003 Feb; 49(2):109-14. PubMed ID: 12728577
[TBL] [Abstract][Full Text] [Related]
35. [Chlamydia pneumoniae and arteriosclerosis: an innocent onlooker?].
Vidal Verdú E
An Med Interna; 1999 Jul; 16(7):329-32. PubMed ID: 10481330
[No Abstract] [Full Text] [Related]
36. Potential infectious etiologies of atherosclerosis: a multifactorial perspective.
O'Connor S; Taylor C; Campbell LA; Epstein S; Libby P
Emerg Infect Dis; 2001; 7(5):780-8. PubMed ID: 11747688
[TBL] [Abstract][Full Text] [Related]
37. Chlamydia pneumoniae and atherosclerosis: the role of mast cells.
Di Pietro M; Schiavoni G; Del Piano M; Shaik Y; Boscolo P; Caraffa A; Grano M; Teté S; Conti F; Sessa R
J Biol Regul Homeost Agents; 2009; 23(2):65-9. PubMed ID: 19589286
[TBL] [Abstract][Full Text] [Related]
38. Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial.
Dunne MW
J Infect Dis; 2000 Jun; 181 Suppl 3():S572-8. PubMed ID: 10839762
[TBL] [Abstract][Full Text] [Related]
39. Opinion article: cytomegalovirus is a risk factor in atherogenesis.
Reinhardt B; Minisini R; Mertens T
Herpes; 2002 Apr; 9(1):21-3. PubMed ID: 11916496
[TBL] [Abstract][Full Text] [Related]
40. Atherogenetically relevant cells support continuous growth of Chlamydia pneumoniae.
Maass M; Gieffers J; Solbach W
Herz; 2000 Mar; 25(2):68-72. PubMed ID: 10829241
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
